China
Africa
Explore chapters and articles related to this topic
Monographs of Topical Drugs that Have Caused Contact Allergy/Allergic Contact Dermatitis
Published in Anton C. de Groot, Monographs in Contact Allergy, 2021
The results of patch testing with desoximetasone in consecutive patients suspected of contact dermatitis (routine testing) and of testing in groups of selected patients (individuals suspected of corticosteroid allergy, patients previously reacting to tixocortol pivalate) are shown in table 3.92.1. Desoximetasone has been included in the screening series of the North American Contact Dermatitis group since 2007, and prevalences of sensitization since then have been invariably very low, 0.1% or 0.2%. Definite + probable relevance rates varied widely, ranging from 0% to 83% (1–5,13). In 2 studies in groups of selected patients, the frequencies of positive patch tests were also low: 0.4% (12) and 1.0% (14).
Caterpillars (Urticating)
Published in Gail Miriam Moraru, Jerome Goddard, The Goddard Guide to Arthropods of Medical Importance, Seventh Edition, 2019
Gail Miriam Moraru, Jerome Goddard
Local treatment of urticating caterpillar stings consists of careful repeated stripping of the sting site with adhesive or cellophane tape to remove the spines (if the offending species was stout-spined), application of ice packs, and oral administration of antihistamines to help relieve itching and burning sensations. Acute urticarial lesions may be further relieved by the application of topical corticosteroids, which help reduce the intensity of the inflammatory reaction. Allen et al.11 reported good results with desoximetasone gel applied twice daily to the affected areas. Rosen10 observed that systemic administration of corticosteroids in the form of intramuscular triamcinolone acetonide has been remarkably effective in relieving both severe itching due to gypsy moth dermatitis and pain due to puss caterpillar dermatitis.
Study of pediatric compounded drug prescriptions in a health care facility in Bandung
Published in Elida Zairina, Junaidi Khotib, Chrismawan Ardianto, Syed Azhar Syed Sulaiman, Charles D. Sands, Timothy E. Welty, Unity in Diversity and the Standardisation of Clinical Pharmacy Services, 2017
F. Lestari, Y. Aryanti, U. Yuniarni
Topical desoximetasone has not been determined in efficacy and safety for children under 10 years old. Topical clobetasol propionate is not recommended for children under 12 years old. Children are more susceptible to suppression in HPA-axis and Cushing syndrome induced by topical corticosteroid than adultsbecauseof surface area larger than body weight ratio, especially when topical corticosteroid applied for above 20% on body surface area. The risk of adrenal suppression increased in younger age. It manifested in growth retardation, lower body weight, lower plasma cortisol concentration, and a lack of response to corticotropine stimulation (American Society of Health-System Pharmacists 2011).
Is topical treatment effective for psoriasis in patients who failed topical treatment?
Published in Journal of Dermatological Treatment, 2021
Nwanneka Okwundu, Leah Cardwell, Abigail Cline, Irma Richardson, Steven R. Feldman
All study subjects received desoximetasone spray 0.25% (Topicort, Taro Pharmaceuticals) twice daily for 14 days. At the baseline visit, six of the subjects were randomly selected to also receive a twice daily reminder call. Study visits occurred frequently (at baseline, Day 3, Day 7, and Day 14) in order to further assure good adherence to the treatment regimen. During visits, disease severity was scored with Pruritus Visual Analog Scale (VAS), Psoriasis Area and Severity Index (PASI), Total Lesion Severity Score (TLSS), and Investigator Global Assessment (IGA). Descriptive statistics were used to report the outcomes for each subject. The study was designed to assess how many of the ‘topical treatment resistant’ subjects would improve with topical treatment but was not designed nor powered to test whether the phone call reminders increased adherence.
Histiocytoid Sweet syndrome successfully treated with etanercept
Published in Baylor University Medical Center Proceedings, 2018
Ian T. Watson, Isabel Haugh, Alexis R. Gardner, M. Alan Menter
Fourteen months after the initial consultation, the patient experienced extensive oral lesions preventing her from eating. Other therapeutic options were then explored. Infliximab 5 mg/kg was initiated at this time, resulting in complete response, but was discontinued after 3 months due to elevated liver function assay. Four months after cessation of infliximab and 26 months following initial consultation, a twice-weekly 1 mg/kg subcutaneous etanercept and 0.05% topical desoximetasone regimen was initiated, leading to a dramatic improvement of symptoms within 1 month. Our patient experienced almost complete remission with only periodic, isolated recurrence while on continued etanercept twice weekly and as-needed 0.05% topical desoximetasone for 37 months since beginning this treatment regimen.
4-Day evaluation of the irritation potential of topical desoximetasone 0.25% and 0.05% spray on light-exposed skin
Published in Journal of Dermatological Treatment, 2018
Nupur U. Patel, Alexandra Grammenos, Asha Gowda, Omobola Onikoyi, Steven R. Feldman
Desoximetasone is a potent synthetic corticosteroid that has been used in clinical medicine for over 40 years. It is a glucocorticoid receptor agonist, which upon binding, translocates to the nucleus and binds specific DNA domains to alter gene transcription (1). Through a cascade of events, desoximetasone exhibits many metabolic and immunosuppressive actions. Although the absolute mechanisms of action of corticosteroids are unclear, one of its main roles is to mediate anti-inflammatory reactions (1). Corticosteroids are known to induce proteins that inhibit phospholipase A2, which ultimately prevents the release of arachidonic acid and the biosynthesis of downstream inflammatory mediators such as leukotrienes. In addition to its anti-inflammatory effects, corticosteroids are primarily effective because of their antipruritic and vasoconstrictive actions (1). These properties indicate topical corticosteroids for the treatment and control of chronic inflammation and autoimmune reactions of the skin.